Agalsidase alfa was well tolerated throughout the observation period, and no clinical problem occurred after the reintroduction of agalsidase beta in patients who switched back. Despite the exiguous number of patients involved in this observation, and considering that 80% of the patients treated with this drug were males, who are more prone to disease progression, these data offer further information about the safety and efficacy of agalsidase alfa.
Agalsidase alfa and agalsidase beta in the treatment of fabry disease: Does the dose really matter?
Riccio Eleonora;
2015
Abstract
Agalsidase alfa was well tolerated throughout the observation period, and no clinical problem occurred after the reintroduction of agalsidase beta in patients who switched back. Despite the exiguous number of patients involved in this observation, and considering that 80% of the patients treated with this drug were males, who are more prone to disease progression, these data offer further information about the safety and efficacy of agalsidase alfa.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
